by Nitesh Kuhadiya, MD, MPH
Since the landmark discovery of insulin treatment of type1 diabetes has centered mainly on preparations of insulin, but adequate blood sugar control in patients with type 1 diabetes still continues to be a major challenge. Even in patients with an A1c less than 7%, blood sugars are often erratic. This leads to frustration for the patient and the treating physician as new means are being sought to improve blood sugar control for these patients.
In 2011, research conducted at SUNY Buffalo showed for the first time that a once-a-day injection of a drug called Liraglutide (Victoza) in addition to insulin reduced average fasting and weekly blood sugars. There was also a reduction in blood sugar oscillations. Use of Victoza was also associated with a decrease in insulin requirements. Finally, there was a weight loss of almost 10 pounds over a period of 24 weeks!
With the use of Victoza the SUNY Buffalo team has also found similar benefits in poorly controlled and obese patients. These patients had type1 diabetes and an average weight of 212 pounds. This is extremely relevant, since most patients with type1 diabetes are not well controlled, and over 50% of patients with type1 diabetes in the United States are obese.
These results are exciting. Now, the Endocrinology Division of the University at Buffalo is conducting studies to determine the effects of Victoza in local patients with type1 diabetes. If you are interested in participating in this clinical trial please visit www.ubdiabetes.com or call 716-626-7998 for more information.
About the Author
Nitesh Kuhadiya is an endocrinology fellow in the Division of Endocrinology and Metabolism, University at Buffalo. Dr. Kuhadiya is a member of the research team of Dr. Paresh Dandona that is conducting four randomized placebo controlled trials on the effect of Victoza in type1 diabetes.
Since the landmark discovery of insulin treatment of type1 diabetes has centered mainly on preparations of insulin, but adequate blood sugar control in patients with type 1 diabetes still continues to be a major challenge. Even in patients with an A1c less than 7%, blood sugars are often erratic. This leads to frustration for the patient and the treating physician as new means are being sought to improve blood sugar control for these patients.
In 2011, research conducted at SUNY Buffalo showed for the first time that a once-a-day injection of a drug called Liraglutide (Victoza) in addition to insulin reduced average fasting and weekly blood sugars. There was also a reduction in blood sugar oscillations. Use of Victoza was also associated with a decrease in insulin requirements. Finally, there was a weight loss of almost 10 pounds over a period of 24 weeks!
With the use of Victoza the SUNY Buffalo team has also found similar benefits in poorly controlled and obese patients. These patients had type1 diabetes and an average weight of 212 pounds. This is extremely relevant, since most patients with type1 diabetes are not well controlled, and over 50% of patients with type1 diabetes in the United States are obese.
These results are exciting. Now, the Endocrinology Division of the University at Buffalo is conducting studies to determine the effects of Victoza in local patients with type1 diabetes. If you are interested in participating in this clinical trial please visit www.ubdiabetes.com or call 716-626-7998 for more information.
About the Author
Nitesh Kuhadiya is an endocrinology fellow in the Division of Endocrinology and Metabolism, University at Buffalo. Dr. Kuhadiya is a member of the research team of Dr. Paresh Dandona that is conducting four randomized placebo controlled trials on the effect of Victoza in type1 diabetes.
No comments:
Post a Comment